Tirzepatide Lowers albuminuria among Type 2 Diabetes Patients: Study

This post hoc analysis used data from the combined SURPASS-1–5 trials, including baseline UACR ≥30 mg/g subgroups. A mixed model for repeated measures was used to compare on-treatment changes in UACR from baseline through to the last treatment visit. Study identifier was entered into the model as a covariate to account for variability between trials.

Key Findings

• Tirzepatide 5 mg, 10 mg, and 15 mg doses substantially decreased UACR compared with all combined comparators.

• 5 mg dose: -19.3% (95% CI -25.5, -12.5)

• 10 mg dose: -22.0% (95% CI -28.1, -15.3)

• 15 mg dose: -26.3% (95% CI -32.0, -20.0)

• Decrease in UACR was seen across all comparators, including placebo, active treatments, and insulin-based treatments.

• In patients with baseline UACR vastly above or equal to 30 mg/g, there was a notable improvement, suggesting significant benefit in chronic albuminuric patients.

• Mediation analysis indicated that weight loss caused by tirzepatide mediated about 50% of the reduction in albuminuria.

• The eGFR during the course of the study never varied more than 6.57 points between the comparator and the tirzepatide combination at week 40/42.

The study authors found that tirzepatide demonstrated reduction in UACR, validating its role in kidney protection in patients with type 2 diabetes. These findings are encouraging of the evaluation of tirzepatide in the treatment of diabetes, especially in those with pre-existing renal abnormality.

Reference: